US2020113533A1PendingUtilityA1
Methods for treating idiopathic pulmonary fibrosis
Est. expiryMay 3, 2032(~5.8 yrs left)· nominal 20-yr term from priority
A61B 6/50A61K 2039/505A61B 6/032A61B 6/5217A61K 49/0004A61K 39/3955C07K 16/22
62
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (IPF) by administering anti-CTGF antibodies. Methods for prognosing individuals with IPF are also provided.
Claims
exact text as granted — not AI-modified1 - 24 . (canceled)
25 . A method for increasing forced vital capacity (FVC) in a subject with idiopathic pulmonary fibrosis (IPF), the method comprising administering at least 30 mg/kg of an anti-connective tissue growth factor (CTGF) antibody that has the same amino acid sequence as the antibody produced by the cell line identified by ATCC Accession No. PTA-6006, thereby increasing the subject's FVC.
26 . The method of claim 25 , further comprising the administration of an additional therapeutic agent selected from the group consisting of pirfenidone, nintedanib, corticosteroids, antibiotics, immunosuppressivw drugs and supplemental oxygen.Join the waitlist — get patent alerts
Track US2020113533A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.